Stem definition | Drug id | CAS RN |
---|---|---|
NO2 - derivatives | 1949 | 67-20-9 |
Dose | Unit | Route |
---|---|---|
0.20 | g | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 4 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 0.19 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 47 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 24 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 87 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 0.57 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 9.70 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.17 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 0.97 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Feb. 6, 1953 | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Urinary tract infection | 563.00 | 10.66 | 779 | 38198 | 239124 | 53070965 |
Drug hypersensitivity | 354.12 | 10.66 | 667 | 38310 | 264575 | 53045514 |
Autoimmune hepatitis | 208.99 | 10.66 | 108 | 38869 | 8210 | 53301879 |
Cystitis | 180.12 | 10.66 | 196 | 38781 | 46792 | 53263297 |
Rheumatoid arthritis | 123.89 | 10.66 | 38 | 38939 | 314493 | 52995596 |
Drug ineffective | 107.89 | 10.66 | 278 | 38699 | 816967 | 52493122 |
Jaundice | 96.69 | 10.66 | 115 | 38862 | 30198 | 53279891 |
Pulmonary toxicity | 86.15 | 10.66 | 52 | 38925 | 5339 | 53304750 |
Contraindicated product administered | 73.65 | 10.66 | 7 | 38970 | 135622 | 53174467 |
Drug-induced liver injury | 69.71 | 10.66 | 96 | 38881 | 29137 | 53280952 |
Infusion related reaction | 68.65 | 10.66 | 15 | 38962 | 155942 | 53154147 |
Pulmonary fibrosis | 60.18 | 10.66 | 81 | 38896 | 24054 | 53286035 |
Injury | 58.92 | 10.66 | 121 | 38856 | 50850 | 53259239 |
Therapeutic product effect decreased | 51.55 | 10.66 | 14 | 38963 | 125641 | 53184448 |
Drug intolerance | 51.06 | 10.66 | 45 | 38932 | 205448 | 53104641 |
Lip swelling | 49.94 | 10.66 | 79 | 38898 | 27122 | 53282967 |
Off label use | 48.25 | 10.66 | 180 | 38797 | 472032 | 52838057 |
Interstitial lung disease | 44.49 | 10.66 | 118 | 38859 | 58504 | 53251585 |
Systemic lupus erythematosus | 42.80 | 10.66 | 19 | 38958 | 125395 | 53184694 |
Glossodynia | 39.61 | 10.66 | 12 | 38965 | 100279 | 53209810 |
Systemic inflammatory response syndrome | 37.62 | 10.66 | 32 | 38945 | 5628 | 53304461 |
Treatment failure | 37.16 | 10.66 | 24 | 38953 | 128379 | 53181710 |
Arthropathy | 36.31 | 10.66 | 30 | 38947 | 141423 | 53168666 |
Kidney infection | 34.48 | 10.66 | 55 | 38922 | 19012 | 53291077 |
Oesophageal spasm | 34.04 | 10.66 | 22 | 38955 | 2546 | 53307543 |
Hepatic fibrosis | 33.75 | 10.66 | 24 | 38953 | 3249 | 53306840 |
Heart sounds | 32.95 | 10.66 | 13 | 38964 | 522 | 53309567 |
Wound | 32.63 | 10.66 | 13 | 38964 | 91544 | 53218545 |
Malaise | 31.03 | 10.66 | 398 | 38579 | 357219 | 52952870 |
Oesophageal pain | 30.77 | 10.66 | 22 | 38955 | 3004 | 53307085 |
Emotional distress | 29.71 | 10.66 | 70 | 38907 | 32247 | 53277842 |
Amblyopia | 29.38 | 10.66 | 10 | 38967 | 262 | 53309827 |
Pericarditis | 28.72 | 10.66 | 6 | 38971 | 64400 | 53245689 |
Pollakiuria | 28.28 | 10.66 | 60 | 38917 | 25779 | 53284310 |
Cardiac murmur | 28.21 | 10.66 | 39 | 38938 | 11874 | 53298215 |
Dysuria | 28.04 | 10.66 | 66 | 38911 | 30387 | 53279702 |
Prolonged expiration | 27.56 | 10.66 | 12 | 38965 | 620 | 53309469 |
Eosinophilia | 27.47 | 10.66 | 53 | 38924 | 21282 | 53288807 |
Febrile neutropenia | 27.24 | 10.66 | 22 | 38955 | 104914 | 53205175 |
Multiple sclerosis relapse | 26.94 | 10.66 | 83 | 38894 | 44770 | 53265319 |
Joint swelling | 26.90 | 10.66 | 85 | 38892 | 234553 | 53075536 |
Costovertebral angle tenderness | 26.56 | 10.66 | 7 | 38970 | 73 | 53310016 |
Swollen tongue | 26.09 | 10.66 | 65 | 38912 | 31015 | 53279074 |
Bladder disorder | 25.26 | 10.66 | 30 | 38947 | 7858 | 53302231 |
Hepatic cirrhosis | 24.72 | 10.66 | 46 | 38931 | 17976 | 53292113 |
Hypersensitivity pneumonitis | 24.57 | 10.66 | 18 | 38959 | 2552 | 53307537 |
Death | 24.34 | 10.66 | 157 | 38820 | 357075 | 52953014 |
Change of bowel habit | 24.29 | 10.66 | 16 | 38961 | 1912 | 53308177 |
Uterine perforation | 23.40 | 10.66 | 28 | 38949 | 7391 | 53302698 |
Liver function test abnormal | 22.68 | 10.66 | 82 | 38895 | 47989 | 53262100 |
Pyelonephritis | 22.61 | 10.66 | 42 | 38935 | 16395 | 53293694 |
Urosepsis | 22.29 | 10.66 | 42 | 38935 | 16568 | 53293521 |
Multiple sclerosis | 21.97 | 10.66 | 56 | 38921 | 27097 | 53282992 |
Neurogenic bladder | 21.81 | 10.66 | 18 | 38959 | 3038 | 53307051 |
Escherichia urinary tract infection | 21.27 | 10.66 | 33 | 38944 | 11140 | 53298949 |
Atrioventricular block first degree | 21.17 | 10.66 | 25 | 38952 | 6510 | 53303579 |
Nephrolithiasis | 21.14 | 10.66 | 67 | 38910 | 36680 | 53273409 |
Alopecia | 21.01 | 10.66 | 94 | 38883 | 234489 | 53075600 |
Chromaturia | 21.00 | 10.66 | 40 | 38937 | 15910 | 53294179 |
Neutropenia | 20.92 | 10.66 | 54 | 38923 | 159131 | 53150958 |
Drug abuse | 20.71 | 10.66 | 11 | 38966 | 65515 | 53244574 |
Rales | 20.63 | 10.66 | 32 | 38945 | 10800 | 53299289 |
Liver transplant | 20.59 | 10.66 | 16 | 38961 | 2478 | 53307611 |
Cystitis interstitial | 20.47 | 10.66 | 13 | 38964 | 1460 | 53308629 |
Cholecystitis chronic | 19.93 | 10.66 | 31 | 38946 | 10487 | 53299602 |
Ureteric obstruction | 19.84 | 10.66 | 14 | 38963 | 1872 | 53308217 |
Liver injury | 19.37 | 10.66 | 47 | 38930 | 22056 | 53288033 |
Urine odour abnormal | 19.28 | 10.66 | 22 | 38955 | 5524 | 53304565 |
Intentional overdose | 18.84 | 10.66 | 13 | 38964 | 67192 | 53242897 |
Acute hepatic failure | 18.50 | 10.66 | 39 | 38938 | 16681 | 53293408 |
Anhedonia | 18.20 | 10.66 | 30 | 38947 | 10657 | 53299432 |
Chronic hepatitis | 18.15 | 10.66 | 10 | 38967 | 864 | 53309225 |
Drug reaction with eosinophilia and systemic symptoms | 18.14 | 10.66 | 59 | 38918 | 32741 | 53277348 |
Hepatic enzyme increased | 18.01 | 10.66 | 41 | 38936 | 126154 | 53183935 |
Overdose | 17.94 | 10.66 | 32 | 38945 | 107704 | 53202385 |
Foetal heart rate decreased | 17.67 | 10.66 | 6 | 38971 | 156 | 53309933 |
Jaundice cholestatic | 17.64 | 10.66 | 21 | 38956 | 5513 | 53304576 |
Urine analysis abnormal | 17.62 | 10.66 | 19 | 38958 | 4481 | 53305608 |
Completed suicide | 17.31 | 10.66 | 48 | 38929 | 138153 | 53171936 |
Myelocyte percentage increased | 17.29 | 10.66 | 6 | 38971 | 167 | 53309922 |
Pseudophaeochromocytoma | 17.18 | 10.66 | 5 | 38972 | 77 | 53310012 |
Rectal polyp | 17.10 | 10.66 | 10 | 38967 | 968 | 53309121 |
Flank pain | 17.08 | 10.66 | 34 | 38943 | 13962 | 53296127 |
Fracture displacement | 17.04 | 10.66 | 11 | 38966 | 1270 | 53308819 |
Hallucination | 16.87 | 10.66 | 81 | 38896 | 53757 | 53256332 |
Acute febrile neutrophilic dermatosis | 16.48 | 10.66 | 15 | 38962 | 2886 | 53307203 |
Therapeutic product effect incomplete | 16.45 | 10.66 | 26 | 38951 | 91758 | 53218331 |
Colour blindness acquired | 16.40 | 10.66 | 5 | 38972 | 91 | 53309998 |
Product use issue | 16.38 | 10.66 | 50 | 38927 | 139534 | 53170555 |
Breath sounds abnormal | 16.08 | 10.66 | 25 | 38952 | 8452 | 53301637 |
Respiration abnormal | 16.07 | 10.66 | 20 | 38957 | 5498 | 53304591 |
Hiccups | 16.03 | 10.66 | 12 | 38965 | 1758 | 53308331 |
Bladder irritation | 15.88 | 10.66 | 6 | 38971 | 214 | 53309875 |
Urine oxalate increased | 15.85 | 10.66 | 6 | 38971 | 215 | 53309874 |
Band neutrophil percentage increased | 15.72 | 10.66 | 6 | 38971 | 220 | 53309869 |
Toxicity to various agents | 15.71 | 10.66 | 95 | 38882 | 219503 | 53090586 |
Therapy interrupted | 15.63 | 10.66 | 40 | 38937 | 19396 | 53290693 |
Umbilical cord around neck | 15.60 | 10.66 | 6 | 38971 | 225 | 53309864 |
Bladder operation | 15.49 | 10.66 | 9 | 38968 | 861 | 53309228 |
Traumatic lung injury | 15.32 | 10.66 | 11 | 38966 | 1512 | 53308577 |
Upper respiratory tract congestion | 15.30 | 10.66 | 12 | 38965 | 1883 | 53308206 |
Hepatitis | 15.30 | 10.66 | 57 | 38920 | 33837 | 53276252 |
Lymphoedema | 14.98 | 10.66 | 26 | 38951 | 9627 | 53300462 |
Subacute cutaneous lupus erythematosus | 14.95 | 10.66 | 13 | 38964 | 2355 | 53307734 |
Oesophageal cancer metastatic | 14.88 | 10.66 | 5 | 38972 | 126 | 53309963 |
Wheezing | 14.87 | 10.66 | 90 | 38887 | 65185 | 53244904 |
Eosinophilic pleural effusion | 14.82 | 10.66 | 4 | 38973 | 46 | 53310043 |
Blood urine present | 14.71 | 10.66 | 31 | 38946 | 13254 | 53296835 |
Urine leukocyte esterase positive | 14.41 | 10.66 | 14 | 38963 | 2922 | 53307167 |
Retinal depigmentation | 14.39 | 10.66 | 6 | 38971 | 278 | 53309811 |
Sensitisation | 14.18 | 10.66 | 10 | 38967 | 1335 | 53308754 |
Abdominal discomfort | 14.10 | 10.66 | 99 | 38878 | 220963 | 53089126 |
Lower urinary tract symptoms | 14.10 | 10.66 | 4 | 38973 | 56 | 53310033 |
Anaemia | 13.96 | 10.66 | 132 | 38845 | 276586 | 53033503 |
Hepatic necrosis | 13.88 | 10.66 | 19 | 38958 | 5731 | 53304358 |
Hepatitis acute | 13.82 | 10.66 | 24 | 38953 | 8892 | 53301197 |
Appetite disorder | 13.41 | 10.66 | 20 | 38957 | 6523 | 53303566 |
Depressive symptom | 13.17 | 10.66 | 14 | 38963 | 3250 | 53306839 |
Micturition urgency | 13.13 | 10.66 | 23 | 38954 | 8579 | 53301510 |
Retroperitoneal fibrosis | 13.12 | 10.66 | 6 | 38971 | 348 | 53309741 |
Band neutrophil count increased | 12.93 | 10.66 | 6 | 38971 | 360 | 53309729 |
Arthralgia | 12.89 | 10.66 | 235 | 38742 | 439548 | 52870541 |
Walking aid user | 12.87 | 10.66 | 19 | 38958 | 6139 | 53303950 |
Muscle injury | 12.81 | 10.66 | 3 | 38974 | 29763 | 53280326 |
Intestinal haemorrhage | 12.56 | 10.66 | 14 | 38963 | 3426 | 53306663 |
Specific gravity urine decreased | 12.53 | 10.66 | 7 | 38970 | 621 | 53309468 |
Myelocyte count increased | 12.53 | 10.66 | 6 | 38971 | 387 | 53309702 |
Urinary tract infection bacterial | 12.51 | 10.66 | 16 | 38961 | 4518 | 53305571 |
Cholelithiasis | 12.38 | 10.66 | 61 | 38916 | 40903 | 53269186 |
Clostridium difficile colitis | 12.26 | 10.66 | 37 | 38940 | 19728 | 53290361 |
Cardio-respiratory arrest | 12.17 | 10.66 | 15 | 38962 | 58743 | 53251346 |
Pneumonia viral | 12.16 | 10.66 | 20 | 38957 | 7092 | 53302997 |
Folliculitis | 12.15 | 10.66 | 4 | 38973 | 31705 | 53278384 |
Urinary retention | 12.13 | 10.66 | 47 | 38930 | 28419 | 53281670 |
Culture urine positive | 12.12 | 10.66 | 14 | 38963 | 3561 | 53306528 |
Hydronephrosis | 12.03 | 10.66 | 23 | 38954 | 9173 | 53300916 |
Chronic kidney disease | 12.00 | 10.66 | 63 | 38914 | 43307 | 53266782 |
Swelling | 11.98 | 10.66 | 86 | 38891 | 191019 | 53119070 |
Rash macular | 11.98 | 10.66 | 38 | 38939 | 20809 | 53289280 |
Lichen sclerosus | 11.86 | 10.66 | 8 | 38969 | 994 | 53309095 |
Klebsiella test positive | 11.64 | 10.66 | 8 | 38969 | 1025 | 53309064 |
Product contamination microbial | 11.58 | 10.66 | 5 | 38972 | 253 | 53309836 |
Knee arthroplasty | 11.58 | 10.66 | 5 | 38972 | 33564 | 53276525 |
Irritable bowel syndrome | 11.50 | 10.66 | 9 | 38968 | 43623 | 53266466 |
Meconium in amniotic fluid | 11.47 | 10.66 | 5 | 38972 | 259 | 53309830 |
Adverse event | 11.43 | 10.66 | 8 | 38969 | 41053 | 53269036 |
Vulvovaginal swelling | 11.39 | 10.66 | 6 | 38971 | 474 | 53309615 |
Haematuria | 11.39 | 10.66 | 46 | 38931 | 28343 | 53281746 |
Discomfort | 11.34 | 10.66 | 34 | 38943 | 95438 | 53214651 |
Abdominal rigidity | 11.30 | 10.66 | 10 | 38967 | 1854 | 53308235 |
Musculoskeletal stiffness | 11.29 | 10.66 | 49 | 38928 | 123319 | 53186770 |
Monocyte percentage increased | 11.27 | 10.66 | 8 | 38969 | 1079 | 53309010 |
Gallbladder disorder | 11.26 | 10.66 | 34 | 38943 | 18131 | 53291958 |
Pulmonary arterial hypertension | 11.16 | 10.66 | 3 | 38974 | 27119 | 53282970 |
Leukocyturia | 11.14 | 10.66 | 8 | 38969 | 1099 | 53308990 |
Therapeutic response decreased | 11.11 | 10.66 | 11 | 38966 | 47558 | 53262531 |
Psoriasis | 11.09 | 10.66 | 30 | 38947 | 87059 | 53223030 |
White blood cells urine positive | 10.94 | 10.66 | 15 | 38962 | 4530 | 53305559 |
Traumatic liver injury | 10.94 | 10.66 | 5 | 38972 | 290 | 53309799 |
Rash | 10.80 | 10.66 | 413 | 38564 | 445778 | 52864311 |
Fluid intake reduced | 10.79 | 10.66 | 13 | 38964 | 3456 | 53306633 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Urinary tract infection | 187.26 | 17.43 | 138 | 5820 | 79933 | 32427635 |
Exposure during pregnancy | 72.83 | 17.43 | 35 | 5923 | 9194 | 32498374 |
Urosepsis | 40.69 | 17.43 | 26 | 5932 | 11864 | 32495704 |
Oxidative stress | 36.84 | 17.43 | 7 | 5951 | 66 | 32507502 |
Pulmonary fibrosis | 36.69 | 17.43 | 28 | 5930 | 16946 | 32490622 |
Protein total abnormal | 30.66 | 17.43 | 8 | 5950 | 343 | 32507225 |
Pulmonary valve stenosis | 30.22 | 17.43 | 8 | 5950 | 363 | 32507205 |
Prostatitis | 29.82 | 17.43 | 16 | 5942 | 5284 | 32502284 |
Skin depigmentation | 29.41 | 17.43 | 8 | 5950 | 403 | 32507165 |
Cardiac murmur | 27.81 | 17.43 | 17 | 5941 | 7174 | 32500394 |
Foetal exposure during pregnancy | 27.78 | 17.43 | 36 | 5922 | 41265 | 32466303 |
Hair colour changes | 25.14 | 17.43 | 10 | 5948 | 1667 | 32505901 |
Haematuria | 24.81 | 17.43 | 37 | 5921 | 48324 | 32459244 |
Tendonitis | 24.79 | 17.43 | 17 | 5941 | 8718 | 32498850 |
Urinary retention | 23.82 | 17.43 | 31 | 5927 | 35666 | 32471902 |
Culture urine positive | 23.62 | 17.43 | 9 | 5949 | 1338 | 32506230 |
Tooth injury | 23.45 | 17.43 | 8 | 5950 | 867 | 32506701 |
Porphyria non-acute | 23.28 | 17.43 | 7 | 5951 | 505 | 32507063 |
Atrial septal defect | 23.14 | 17.43 | 15 | 5943 | 7010 | 32500558 |
Breast inflammation | 22.79 | 17.43 | 4 | 5954 | 23 | 32507545 |
Melanocytic naevus | 22.78 | 17.43 | 10 | 5948 | 2131 | 32505437 |
Plantar fasciitis | 22.33 | 17.43 | 8 | 5950 | 1001 | 32506567 |
Multiple sclerosis | 21.98 | 17.43 | 15 | 5943 | 7629 | 32499939 |
Patent ductus arteriosus | 21.57 | 17.43 | 11 | 5947 | 3274 | 32504294 |
Clonic convulsion | 21.54 | 17.43 | 7 | 5951 | 652 | 32506916 |
Blood chromogranin A increased | 19.50 | 17.43 | 5 | 5953 | 200 | 32507368 |
Eye swelling | 18.96 | 17.43 | 15 | 5943 | 9557 | 32498011 |
Therapy interrupted | 18.95 | 17.43 | 14 | 5944 | 8064 | 32499504 |
Multiple congenital abnormalities | 18.78 | 17.43 | 6 | 5952 | 530 | 32507038 |
Skin exfoliation | 18.61 | 17.43 | 23 | 5935 | 25134 | 32482434 |
Carcinoid crisis | 18.39 | 17.43 | 5 | 5953 | 251 | 32507317 |
Defaecation urgency | 18.17 | 17.43 | 8 | 5950 | 1717 | 32505851 |
Gastric ulcer | 17.80 | 17.43 | 18 | 5940 | 15791 | 32491777 |
Bone neoplasm | 17.63 | 17.43 | 5 | 5953 | 294 | 32507274 |
Source | Code | Description |
---|---|---|
ATC | J01XE01 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER ANTIBACTERIALS Nitrofuran derivatives |
ATC | J01XE51 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER ANTIBACTERIALS Nitrofuran derivatives |
FDA CS | M0014892 | Nitrofurans |
FDA EPC | N0000175494 | Nitrofuran Antibacterial |
MeSH PA | D000900 | Anti-Bacterial Agents |
MeSH PA | D000890 | Anti-Infective Agents |
MeSH PA | D000892 | Anti-Infective Agents, Urinary |
CHEBI has role | CHEBI:35441 | anti-infective drugs |
CHEBI has role | CHEBI:36047 | antibacterial drugs |
CHEBI has role | CHEBI:50908 | agente hepatotoxico |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Klebsiella cystitis | indication | 60867007 | |
Escherichia coli urinary tract infection | indication | 301011002 | |
Staphylococcus Saprophyticus Urinary Tract Infection | indication | ||
Enterobacter Cystitis | indication | ||
Enterococcus Urinary Tract Infection | indication | ||
Staphylococcus Aureus Urinary Tract Infection | indication | ||
Prevention of Bacterial Urinary Tract Infection | off-label use | ||
Anuria | contraindication | 2472002 | DOID:2983 |
Acute hepatitis | contraindication | 37871000 | |
Vitamin B deficiency | contraindication | 47903000 | |
Fibrosis of lung | contraindication | 51615001 | DOID:3770 |
Obstructive hyperbilirubinemia | contraindication | 59848001 | |
Interstitial pneumonia | contraindication | 64667001 | |
Optic neuritis | contraindication | 66760008 | DOID:1210 |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Chronic hepatitis | contraindication | 76783007 | DOID:2237 |
Oliguria | contraindication | 83128009 | |
Cholestatic hepatitis | contraindication | 95556007 | |
Anemia due to enzyme deficiency | contraindication | 111577008 | |
Deficiency of glucose-6-phosphate dehydrogenase | contraindication | 124134002 | DOID:2862 |
Cobalamin deficiency | contraindication | 190634004 | |
Impaired renal function disorder | contraindication | 197663003 | |
Drug-induced hepatitis | contraindication | 235876009 | |
Peripheral nerve disease | contraindication | 302226006 | |
Pseudomembranous enterocolitis | contraindication | 397683000 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 7.28 | acidic |
pKa2 | 0.0 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Glucose-6-phosphate 1-dehydrogenase | Enzyme | WOMBAT-PK | |||||||
CDGSH iron-sulfur domain-containing protein 1 | Unclassified | Ki | 6.09 | CHEMBL |
ID | Source |
---|---|
4018849 | VUID |
N0000147151 | NUI |
D00439 | KEGG_DRUG |
54-87-5 | SECONDARY_CAS_RN |
4018848 | VANDF |
4018849 | VANDF |
C0028156 | UMLSCUI |
CHEBI:71415 | CHEBI |
U6Z | PDB_CHEM_ID |
CHEMBL572 | ChEMBL_ID |
DB00698 | DRUGBANK_ID |
CHEMBL1201000 | ChEMBL_ID |
D009582 | MESH_DESCRIPTOR_UI |
6604200 | PUBCHEM_CID |
488 | INN_ID |
10917 | IUPHAR_LIGAND_ID |
927AH8112L | UNII |
221129 | RXNORM |
181427 | MMSL |
2320 | MMSL |
404 | MMSL |
5179 | MMSL |
5180 | MMSL |
5181 | MMSL |
d00112 | MMSL |
002852 | NDDF |
002853 | NDDF |
002854 | NDDF |
373543005 | SNOMEDCT_US |
37978007 | SNOMEDCT_US |
426476003 | SNOMEDCT_US |
427332002 | SNOMEDCT_US |
85343003 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Nitrofurantoin Macrocrystals | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-1643 | CAPSULE | 50 mg | ORAL | ANDA | 25 sections |
Nitrofurantoin Macrocrystals | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-1645 | CAPSULE | 100 mg | ORAL | ANDA | 25 sections |
Nitrofurantoin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-2023 | CAPSULE | 50 mg | ORAL | ANDA | 25 sections |
Nitrofurantoin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-2024 | CAPSULE | 100 mg | ORAL | ANDA | 25 sections |
Nitrofurantoin (monohydrate/macrocrystals) | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0185-0122 | CAPSULE | 25 mg | ORAL | ANDA | 25 sections |
Nitrofurantoin (monohydrate/macrocrystals) | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0185-0122 | CAPSULE | 75 mg | ORAL | ANDA | 25 sections |
Nitrofurantoin Macrocrystals | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0440-1866 | CAPSULE | 100 mg | ORAL | ANDA | 26 sections |
Nitrofurantoin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0472-1992 | SUSPENSION | 25 mg | ORAL | ANDA | 19 sections |
Nitrofurantoin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-3684 | CAPSULE | 25 mg | ORAL | ANDA | 21 sections |
Nitrofurantoin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-3685 | CAPSULE | 50 mg | ORAL | ANDA | 21 sections |
Nitrofurantoin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-3686 | CAPSULE | 100 mg | ORAL | ANDA | 21 sections |
nitrofurantoin macrocrystals | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7025 | CAPSULE | 100 mg | ORAL | ANDA | 13 sections |
nitrofurantoin macrocrystals | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7026 | CAPSULE | 50 mg | ORAL | ANDA | 13 sections |
nitrofurantoin macrocrystals | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7136 | CAPSULE | 100 mg | ORAL | NDA | 25 sections |
Nitrofurantoin Monohydrate/ Macrocrystalline | HUMAN PRESCRIPTION DRUG LABEL | 2 | 10544-086 | CAPSULE | 25 mg | ORAL | NDA | 28 sections |
Nitrofurantoin Monohydrate/ Macrocrystalline | HUMAN PRESCRIPTION DRUG LABEL | 2 | 10544-086 | CAPSULE | 75 mg | ORAL | NDA | 28 sections |
Nitrofurantoin Macrocrystals | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-601 | CAPSULE | 100 mg | ORAL | ANDA | 24 sections |
Nitrofurantion Macrocrystals | HUMAN PRESCRIPTION DRUG LABEL | 1 | 12634-415 | CAPSULE | 100 mg | ORAL | NDA | 24 sections |
Nitrofurantoin | HUMAN PRESCRIPTION DRUG LABEL | 2 | 13811-719 | CAPSULE | 75 mg | ORAL | ANDA | 25 sections |
Nitrofurantoin | HUMAN PRESCRIPTION DRUG LABEL | 2 | 13811-719 | CAPSULE | 25 mg | ORAL | ANDA | 25 sections |
Nitrofurantoin | Human Prescription Drug Label | 1 | 16571-740 | SUSPENSION | 25 mg | ORAL | NDA AUTHORIZED GENERIC | 19 sections |
NITROFURANTOIN MACROCRYSTALS | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-380 | CAPSULE | 100 mg | ORAL | ANDA | 24 sections |
Nitrofurantoin (monohydrate/macrocrystals) | HUMAN PRESCRIPTION DRUG LABEL | 2 | 16714-439 | CAPSULE | 25 mg | ORAL | ANDA | 23 sections |
Nitrofurantoin (monohydrate/macrocrystals) | HUMAN PRESCRIPTION DRUG LABEL | 2 | 16714-439 | CAPSULE | 75 mg | ORAL | ANDA | 23 sections |
Nitrofurantoin (monohydrate/macrocrystals) | HUMAN PRESCRIPTION DRUG LABEL | 2 | 21695-300 | CAPSULE | 25 mg | ORAL | ANDA | 27 sections |
Nitrofurantoin (monohydrate/macrocrystals) | HUMAN PRESCRIPTION DRUG LABEL | 2 | 21695-300 | CAPSULE | 75 mg | ORAL | ANDA | 27 sections |
Nitrofurantoin Monohydrate/ Macrocrystalline | HUMAN PRESCRIPTION DRUG LABEL | 2 | 33261-160 | CAPSULE | 75 mg | ORAL | NDA | 28 sections |
Nitrofurantoin Monohydrate/ Macrocrystalline | HUMAN PRESCRIPTION DRUG LABEL | 2 | 33261-160 | CAPSULE | 25 mg | ORAL | NDA | 28 sections |
Nitrofurantion Macrocrystals | HUMAN PRESCRIPTION DRUG LABEL | 1 | 33261-226 | CAPSULE | 100 mg | ORAL | NDA | 25 sections |
Nitrofurantoin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 40032-450 | SUSPENSION | 25 mg | ORAL | ANDA | 20 sections |